An observational study in Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), sponsored by Pfizer. Completed at 18 sites in 10 countries. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Cardiomyopathy, Hypertrophic with a site in France — 9 open to participants now, 12 under way, 5 of them phase 3. Cardiomyopathy, Hypertrophic · France.
Among the 33 studies in Cardiomyopathy, Hypertrophic with a site in France, this one is the 4th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2018, is one of 12 observational ones, and was the 16th registered.
364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →9 of the 33 studies in Cardiomyopathy, Hypertrophic with a site in France are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in France, United States, Brazil and 6 more countries
Ages 6+
Rennes University Hospital · Sites in France
Ages 40–80
Imbria Pharmaceuticals, Inc. · Sites in France, United States, Austria and 8 more countries
Ages 18+
Pr. Nicolas GIRERD · Sites in France
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Austria and 6 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 50 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2006; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 812 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 172 across the 21 interventional studies, 297 across the 12 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 33 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
3 of the studies in Cardiomyopathy, Hypertrophic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06481891Phase 3Lexicon PharmaceuticalsA Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | 2027-01 |
| NCT07023614Imbria Pharmaceuticals, Inc.A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | 2026-12 |
| NCT03846297Assistance Publique - Hôpitaux de ParisOptimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Cardiomyopathy, Hypertrophic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) >15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol
Patients with HCM from undiagnosed etiology
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy
Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1
Percentage of participants with cardiac fixation on a radionuclide bone scintigraphy and/or SPECT performed with 99mTc-DPD or 99mTc-PYP or 999mTc-HMDP among participants with LVH from an undiagnosed etiology were reported in this outcome measure. Scintigraphy was defined at each bone site according to the standard grading: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 1
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants With TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a left ventricular (LV) wall thickness greater than or equal to (\>=) 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 2
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags Electronic Case Report Form (e-CRF) part was considered as participants with a senso-motor polyneuropathy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Autonomic Dysfunction: FAS 2
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Autonomic Dysfunction: FAS 3
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Autonomic Dysfunction: FAS 3.1
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Autonomic Dysfunction: FAS 3.2
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Cardiological Manifestations: FAS 2
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval less than (\<) 80 milliseconds (ms) or greater than (\>) 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Cardiological Manifestations: FAS 3
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Cardiological Manifestations: FAS 3.1
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Cardiological Manifestations: FAS 3.2
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Laboratory Abnormalities: FAS 2
Laboratory parameters that were considered as out of range included creatinine \<45 micromole per liter (μmol/L) or greater than 104 μmol/L w; haemoglobin, participants with a value lower than 11.5 grams per deciliter (g/dL) or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 picograms per milliliter (pg/mL); N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Laboratory Abnormalities: FAS 3
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Laboratory Abnormalities: FAS 3.1
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Percentage of Participants With Laboratory Abnormalities: FAS 3.2
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Presence of Neurological Red Flag: FAS1
Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Presence of Neurological Red Flag: FAS 2
Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Discrepancies Between Scintigraphy Result and Single Photon Emission Computed Tomography (SPECT) Result: FAS1
Grade of scintigraphy evaluated by the investigator and Grade of SPECT: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone. Only categories with non-zero values were reported.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Cardiological Assessments - Blood Pressure: FAS 2
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Cardiological Assessments - Blood Pressure: FAS 3
SBP and DBP were evaluated.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Cardiological Assessments - Blood Pressure: FAS 3.1
SBP and DBP were evaluated.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Cardiological Assessments - Blood Pressure: FAS 3.2
SBP and DBP were evaluated.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to History of Clinical Parameters at Baseline: FAS 2
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
Time frame: Baseline
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
Time frame: Baseline
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.1
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
Time frame: Baseline
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.2
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
Time frame: Baseline
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 2
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.1
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.2
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Atrial Fibrillation Assessment: FAS 2
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Atrial Fibrillation Assessment: FAS 3
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Atrial Fibrillation Assessment: FAS 3.1
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Atrial Fibrillation Assessment: FAS 3.2
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 2
Participants who used pacemaker and ICD were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3
Participants who used pacemaker and ICD were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.1
Participants who used pacemaker and ICD were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.2
Participants who used pacemaker and ICD were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 2
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.1
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.2
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 2
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.1
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.2
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Heart Rate Parameter for Participants Without Paced: FAS 2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Heart Rate Parameter for Participants Without Paced: FAS 3
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Heart Rate Parameter for Participants Without Paced: FAS 3.1
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Heart Rate Parameter for Participants Without Paced: FAS 3.2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.1
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 2
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 3
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 3.1
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Sokolow Index: FAS 3.2
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Left Ventricular Ejection Fraction (LVEF): FAS 2
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Left Ventricular Ejection Fraction (LVEF): FAS 3
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Left Ventricular Ejection Fraction (LVEF): FAS 3.1
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Left Ventricular Ejection Fraction (LVEF): FAS 3.2
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 2
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.1
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.2
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 2
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.1
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.2
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV End Diastolic Diameter: FAS 2
Left ventricular end-diastolic diameter (LVEDD) reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV End Diastolic Diameter: FAS 3
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV End Diastolic Diameter: FAS 3.1
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV End Diastolic Diameter: FAS 3.2
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Maximum Wall Thickness: FAS 2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Maximum Wall Thickness: FAS 3
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Maximum Wall Thickness: FAS 3.1
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Maximum Wall Thickness: FAS 3.2
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 2
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 3
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 3.1
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Number of Participants According to Type of Hypertrophic Pattern: FAS 3.2
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV Mass Index (LVMI): FAS 2
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV Mass Index (LVMI): FAS 3
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV Mass Index (LVMI): FAS 3.1
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
LV Mass Index (LVMI): FAS 3.2
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Aortic Valvular Stenosis - Aortic Valve Area: FAS 2
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.1
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.2
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Data of participants diagnosed with left ventricular hypertrophy (LVH) confirmed by bone scintigraphy and/or single photon emission computed tomography (SPECT) and greater than or equal to (\>=) 50 years of age were observed in this study.
| Milestone | All Participants |
|---|---|
| Started | 812 |
| Full analysis set 1 | 766 |
| Full analysis set 2 (subset of fas 1) | 245 |
| Full analysis set 3 (subset of fas 2) | 208 |
| Full analysis set 3.1 | 137 |
| Full analysis set 3.2 | 56 |
| Completed | 766 |
| Not completed | 46 |
| Withdrew: Did not meet inclusion criteria (age less than 50 years) | 2 |
| Withdrew: Scintigraphy was not performed | 44 |
Percentage of participants with cardiac fixation on a radionuclide bone scintigraphy and/or SPECT performed with 99mTc-DPD or 99mTc-PYP or 999mTc-HMDP among participants with LVH from an undiagnosed etiology were reported in this outcome measure. Scintigraphy was defined at each bone site according to the standard grading: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 | 32.0 (28.8 to 35.4) |
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 1 | 17.9 (15.3 to 20.8) |
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1 | 25.2 (22.3 to 28.4) |
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2) | 6.5 (3.8 to 10.8) |
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3) | 6.9 (4.1 to 11.5) |
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1 | 8.7 (4.9 to 14.8) |
Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2 | 3.7 (1.0 to 12.5) |
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2 | 93.5 (89.2 to 96.2) |
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3 | 93.1 (88.5 to 95.9) |
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1 | 91.3 (85.2 to 95.1) |
Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2 | 96.3 (87.5 to 99.0) |
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2 | 13 |
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3 | 13 |
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1 | 11 |
Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants With TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2 | 2 |
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a left ventricular (LV) wall thickness greater than or equal to (\>=) 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1 | 17.1 (14.6 to 19.9) |
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2 | 11.8 (8.4 to 16.5) |
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3 | 9.6 (6.3 to 14.4) |
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1 | 10.9 (6.7 to 17.3) |
Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2 | 7.1 (2.8 to 17.0) |
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags Electronic Case Report Form (e-CRF) part was considered as participants with a senso-motor polyneuropathy.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Senso-Motor Polyneuropathy: FAS 2 | 80.0 (74.5 to 84.5) |
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3 | 86.1 (80.7 to 90.1) |
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1 | 89.8 (83.6 to 93.8) |
Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2 | 85.7 (74.3 to 92.6) |
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2 | 48.6 (42.4 to 54.8) |
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3 | 54.8 (48.0 to 61.4) |
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1 | 60.6 (52.2 to 68.4) |
CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2 | 48.2 (35.7 to 61.0) |
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Autonomic Dysfunction: FAS 2 | 55.9 (49.7 to 62.0) |
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Autonomic Dysfunction: FAS 3 | 58.7 (51.9 to 65.1) |
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Autonomic Dysfunction: FAS 3.1 | 61.3 (53.0 to 69.1) |
Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Autonomic Dysfunction: FAS 3.2 | 57.1 (44.1 to 69.2) |
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval less than (\<) 80 milliseconds (ms) or greater than (\>) 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Cardiological Manifestations: FAS 2 | 98.0 (95.3 to 99.1) |
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Cardiological Manifestations: FAS 3 | 98.1 (95.2 to 99.2) |
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Cardiological Manifestations: FAS 3.1 | 97.8 (93.8 to 99.3) |
Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.
| Percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Cardiological Manifestations: FAS 3.2 | 98.2 (90.6 to 99.7) |
Laboratory parameters that were considered as out of range included creatinine \<45 micromole per liter (μmol/L) or greater than 104 μmol/L w; haemoglobin, participants with a value lower than 11.5 grams per deciliter (g/dL) or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 picograms per milliliter (pg/mL); N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
| Percentage of participants | All Participants |
|---|---|
| Creatinine out of range | 37.6 (31.7 to 43.8) |
| Haemoglobin out of range | 30.2 (24.8 to 36.2) |
| BNP out of range | 62.9 (56.7 to 68.7) |
| NTproBNP out of range | 81.2 (75.9 to 85.6) |
| Troponin I out of range | 3.7 (1.9 to 6.8) |
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
| Percentage of participants | All Participants |
|---|---|
| Creatinine out of range | 42.3 (35.8 to 49.1) |
| Haemoglobin out of range | 33.2 (27.1 to 39.8) |
| BNP out of range | 69.7 (63.2 to 75.6) |
| NTproBNP out of range | 88.9 (84.0 to 92.5) |
| Troponin I out of range | 3.8 (2.0 to 7.4) |
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
| Percentage of participants | All Participants |
|---|---|
| Creatinine out of range | 34.3 (26.9 to 42.6) |
| Haemoglobin out of range | 34.3 (26.9 to 42.6) |
| BNP out of range | 68.6 (60.4 to 75.8) |
| NTproBNP out of range | 90.5 (84.4 to 94.4) |
| Troponin I out of range | 4.4 (2.0 to 9.2) |
Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.
| Percentage of participants | All Participants |
|---|---|
| Creatinine out of range | 58.9 (45.9 to 70.8) |
| Haemoglobin out of range | 35.7 (24.5 to 48.8) |
| BNP out of range | 89.3 (78.5 to 95.0) |
| NTproBNP out of range | 98.2 (90.6 to 99.7) |
| Troponin I out of range | 1.8 (0.3 to 9.4) |
Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.
| Participants | All Participants |
|---|---|
| Yes | 143 |
| No | 623 |
Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.
| Participants | All Participants |
|---|---|
| Yes | 142 |
| No | 103 |
Grade of scintigraphy evaluated by the investigator and Grade of SPECT: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone. Only categories with non-zero values were reported.
| Participants | All Participants |
|---|---|
| Investigator: Grade 0; SPECT: Grade 0 | 43 |
| Investigator: Grade 0; SPECT: Grade 1 | 3 |
| Investigator: Grade 1; SPECT: Grade 1 | 5 |
| Investigator: Grade 2; SPECT: Grade 2 | 16 |
| Investigator: Grade 3; SPECT: Grade 3 | 8 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated.
| mmHg | All Participants |
|---|---|
| DBP | 75.6 ± 12.4 |
| SBP | 132.5 ± 20.0 |
SBP and DBP were evaluated.
| mmHg | All Participants |
|---|---|
| DBP | 74.6 ± 12.0 |
| SBP | 131.0 ± 19.0 |
SBP and DBP were evaluated.
| mmHg | All Participants |
|---|---|
| DBP | 75.6 ± 11.8 |
| SBP | 130.9 ± 18.1 |
SBP and DBP were evaluated.
| mmHg | All Participants |
|---|---|
| DBP | 74.2 ± 11.9 |
| SBP | 131.9 ± 20.5 |
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
| Participants | All Participants |
|---|---|
| Diagnosed hypertension — No | 78 |
| Diagnosed hypertension — Yes | 167 |
| Antihypertensive medication — No | 89 |
| Antihypertensive medication — Yes | 156 |
| Coronary artery disease — No | 184 |
| Coronary artery disease — Yes | 61 |
| Renal insufficiency — No | 177 |
| Renal insufficiency — Yes | 68 |
| Diabetes Mellitus — No | 193 |
| Diabetes Mellitus — Yes | 52 |
| Lumbar spinal stenosis — No | 221 |
| Lumbar spinal stenosis — Yes | 24 |
| Carpal tunnel syndrome — No | 164 |
| Carpal tunnel syndrome — Yes | 81 |
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
| Participants | All Participants |
|---|---|
| Diagnosed hypertension — No | 77 |
| Diagnosed hypertension — Yes | 131 |
| Antihypertensive medication — No | 88 |
| Antihypertensive medication — Yes | 120 |
| Coronary artery disease — No | 162 |
| Coronary artery disease — Yes | 46 |
| Renal insufficiency — No | 147 |
| Renal insufficiency — Yes | 61 |
| Diabetes Mellitus — No | 175 |
| Diabetes Mellitus — Yes | 33 |
| Lumbar spinal stenosis — No | 184 |
| Lumbar spinal stenosis — Yes | 24 |
| Carpal tunnel syndrome — No | 130 |
| Carpal tunnel syndrome — Yes | 78 |
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
| Participants | All Participants |
|---|---|
| Diagnosed hypertension — No | 49 |
| Diagnosed hypertension — Yes | 88 |
| Antihypertensive medication — No | 57 |
| Antihypertensive medication — Yes | 80 |
| Coronary artery disease — No | 112 |
| Coronary artery disease — Yes | 25 |
| Renal insufficiency — No | 102 |
| Renal insufficiency — Yes | 35 |
| Diabetes Mellitus — No | 118 |
| Diabetes Mellitus — Yes | 19 |
| Lumbar spinal stenosis — No | 121 |
| Lumbar spinal stenosis — Yes | 16 |
| Carpal tunnel syndrome — No | 80 |
| Carpal tunnel syndrome — Yes | 57 |
Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.
| Participants | All Participants |
|---|---|
| Diagnosed hypertension — No | 19 |
| Diagnosed hypertension — Yes | 37 |
| Antihypertensive medication — No | 22 |
| Antihypertensive medication — Yes | 34 |
| Coronary artery disease — No | 43 |
| Coronary artery disease — Yes | 13 |
| Renal insufficiency — No | 35 |
| Renal insufficiency — Yes | 21 |
| Diabetes Mellitus — No | 45 |
| Diabetes Mellitus — Yes | 11 |
| Lumbar spinal stenosis — No | 50 |
| Lumbar spinal stenosis — Yes | 6 |
| Carpal tunnel syndrome — No | 37 |
| Carpal tunnel syndrome — Yes | 19 |
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
| Participants | All Participants |
|---|---|
| Class I | 50 |
| Class II | 130 |
| Class III | 57 |
| Class IV | 7 |
| Missing data | 1 |
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
| Participants | All Participants |
|---|---|
| Class I | 45 |
| Class II | 112 |
| Class III | 45 |
| Class IV | 5 |
| Missing data | 1 |
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
| Participants | All Participants |
|---|---|
| Class I | 34 |
| Class II | 69 |
| Class III | 30 |
| Class IV | 3 |
| Missing data | 1 |
Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.
| Participants | All Participants |
|---|---|
| Class I | 5 |
| Class II | 38 |
| Class III | 11 |
| Class IV | 2 |
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 120 |
| Yes permanent | 90 |
| Yes in the past | 35 |
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 105 |
| Yes permanent | 78 |
| Yes in the past | 25 |
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 65 |
| Yes permanent | 52 |
| Yes in the past | 20 |
Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 28 |
| Yes permanent | 23 |
| Yes in the past | 5 |
Participants who used pacemaker and ICD were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Pacemaker — Yes | 30 |
| Pacemaker — No | 215 |
| ICD — Yes | 0 |
| ICD — No | 245 |
Participants who used pacemaker and ICD were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Pacemaker — Yes | 30 |
| Pacemaker — No | 178 |
| ICD — Yes | 0 |
| ICD — No | 208 |
Participants who used pacemaker and ICD were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Pacemaker — Yes | 20 |
| Pacemaker — No | 117 |
| ICD — Yes | 0 |
| ICD — No | 137 |
Participants who used pacemaker and ICD were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Pacemaker — Yes | 7 |
| Pacemaker — No | 49 |
| ICD — Yes | 0 |
| ICD — No | 56 |
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
| Participants | All Participants |
|---|---|
| Negative | 11 |
| Positive | 55 |
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
| Participants | All Participants |
|---|---|
| Negative | 7 |
| Positive | 50 |
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
| Participants | All Participants |
|---|---|
| Negative | 6 |
| Positive | 33 |
Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.
| Participants | All Participants |
|---|---|
| Negative | 0 |
| Positive | 13 |
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 217 |
| Yes | 18 |
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 182 |
| Yes | 18 |
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 122 |
| Yes | 10 |
Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| No | 49 |
| Yes | 6 |
| Beats per minute | All Participants |
|---|---|
| Heart Rate Parameter for Participants Without Paced: FAS 2 | 73.3 ± 15.1 |
| Beats per minute | All Participants |
|---|---|
| Heart Rate Parameter for Participants Without Paced: FAS 3 | 73.2 ± 14.7 |
| Beats per minute | All Participants |
|---|---|
| Heart Rate Parameter for Participants Without Paced: FAS 3.1 | 73.4 ± 15.9 |
| Beats per minute | All Participants |
|---|---|
| Heart Rate Parameter for Participants Without Paced: FAS 3.2 | 72.7 ± 12.1 |
| Participants | All Participants |
|---|---|
| No | 86 |
| Yes | 135 |
| Missing | 6 |
| Participants | All Participants |
|---|---|
| No | 72 |
| Yes | 114 |
| Missing | 4 |
| Participants | All Participants |
|---|---|
| No | 51 |
| Yes | 73 |
| Missing | 3 |
| Participants | All Participants |
|---|---|
| No | 18 |
| Yes | 32 |
| Missing | 0 |
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
| Millimeter | All Participants |
|---|---|
| Sokolow Index: FAS 2 | 19.1 ± 8.8 |
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
| Millimeter | All Participants |
|---|---|
| Sokolow Index: FAS 3 | 18.7 ± 8.6 |
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
| Millimeter | All Participants |
|---|---|
| Sokolow Index: FAS 3.1 | 19.8 ± 8.7 |
Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.
| Millimeter | All Participants |
|---|---|
| Sokolow Index: FAS 3.2 | 16.5 ± 8.4 |
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
| Percentage of blood volume | All Participants |
|---|---|
| Left Ventricular Ejection Fraction (LVEF): FAS 2 | 55.0 ± 11.4 |
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
| Percentage of blood volume | All Participants |
|---|---|
| Left Ventricular Ejection Fraction (LVEF): FAS 3 | 55.2 ± 11.2 |
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
| Percentage of blood volume | All Participants |
|---|---|
| Left Ventricular Ejection Fraction (LVEF): FAS 3.1 | 55.7 ± 11.2 |
LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.
| Percentage of blood volume | All Participants |
|---|---|
| Left Ventricular Ejection Fraction (LVEF): FAS 3.2 | 53.9 ± 11.4 |
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
| Participants | All Participants |
|---|---|
| No | 215 |
| Yes | 26 |
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
| Participants | All Participants |
|---|---|
| No | 183 |
| Yes | 22 |
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
| Participants | All Participants |
|---|---|
| No | 119 |
| Yes | 17 |
LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.
| Participants | All Participants |
|---|---|
| No | 51 |
| Yes | 5 |
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
| Participants | All Participants |
|---|---|
| No | 28 |
| Yes | 62 |
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
| Participants | All Participants |
|---|---|
| No | 26 |
| Yes | 60 |
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
| Participants | All Participants |
|---|---|
| No | 16 |
| Yes | 46 |
Participants were classified according to strain apical preserved as 'No' and 'Yes'.
| Participants | All Participants |
|---|---|
| No | 8 |
| Yes | 12 |
Left ventricular end-diastolic diameter (LVEDD) reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
| Millimeter | All Participants |
|---|---|
| LV End Diastolic Diameter: FAS 2 | 43.3 ± 7.9 |
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
| Millimeter | All Participants |
|---|---|
| LV End Diastolic Diameter: FAS 3 | 43.2 ± 7.9 |
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
| Millimeter | All Participants |
|---|---|
| LV End Diastolic Diameter: FAS 3.1 | 43.2 ± 7.5 |
LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.
| Millimeter | All Participants |
|---|---|
| LV End Diastolic Diameter: FAS 3.2 | 44.4 ± 6.8 |
| Millimeter | All Participants |
|---|---|
| Maximum Wall Thickness: FAS 2 | 17.4 ± 2.5 |
| Millimeter | All Participants |
|---|---|
| Maximum Wall Thickness: FAS 3 | 17.5 ± 2.4 |
| Millimeter | All Participants |
|---|---|
| Maximum Wall Thickness: FAS 3.1 | 17.9 ± 2.5 |
| Millimeter | All Participants |
|---|---|
| Maximum Wall Thickness: FAS 3.2 | 16.9 ± 2.2 |
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
| Participants | All Participants |
|---|---|
| Apical | 6 |
| Concentric | 179 |
| Asymmetric | 47 |
| Mix | 8 |
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
| Participants | All Participants |
|---|---|
| Apical | 4 |
| Concentric | 159 |
| Asymmetric | 37 |
| Mix | 4 |
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
| Participants | All Participants |
|---|---|
| Apical | 1 |
| Concentric | 105 |
| Asymmetric | 27 |
| Mix | 2 |
Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.
| Participants | All Participants |
|---|---|
| Apical | 2 |
| Concentric | 46 |
| Asymmetric | 7 |
| Mix | 1 |
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
| Grams per meter square | All Participants |
|---|---|
| LV Mass Index (LVMI): FAS 2 | 172.7 ± 64.0 |
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
| Grams per meter square | All Participants |
|---|---|
| LV Mass Index (LVMI): FAS 3 | 177.0 ± 53.2 |
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
| Grams per meter square | All Participants |
|---|---|
| LV Mass Index (LVMI): FAS 3.1 | 177.0 ± 48.7 |
Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.
| Grams per meter square | All Participants |
|---|---|
| LV Mass Index (LVMI): FAS 3.2 | 185.5 ± 62.0 |
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
| Centimeter square | All Participants |
|---|---|
| Aortic Valvular Stenosis - Aortic Valve Area: FAS 2 | 2.3 ± 0.8 |
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
| Centimeter square | All Participants |
|---|---|
| Aortic Valvular Stenosis - Aortic Valve Area: FAS 3 | 2.2 ± 0.7 |
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
| Centimeter square | All Participants |
|---|---|
| Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.1 | 2.3 ± 0.7 |
Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.
| Centimeter square | All Participants |
|---|---|
| Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.2 | 2.0 ± 0.7 |
Collected over Not applicable as adverse events were not planned to be collected during the study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | — | — |
Full Analysis Set 1 (FAS1) included all participants who met eligibility criteria and with a radionuclide bone scintigraphy and/or SPECT performed with 99mTechnetium-3,3-diphosphono-1,2-propanodi-carboxylic acid (99mTc-DPD) or 99mTechnetium-pyrophosphate (99mTc-PYP) or 99mTechnetium-hydroxymethylene diphosphonate (99mTc-HMDP).
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 72.3 ± 10.6 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 233 |
| Male | 533 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Caucasian | 665 |
| Caucasian & Portuguese (or Portuguese parents) | 47 |
| African | 21 |
| Asian | 27 |
| Other | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jul 2018 to primary completion in Jun 2022, 46 months.
Results were first posted in Feb 2024, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →